Peginesatide
- Generic Name
- Peginesatide
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 913976-27-9
- Unique Ingredient Identifier
- JX56W9N61Q
- Background
Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life. Chemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself. Peginesatide consists of two 21-amino acid chains that are covalently bonded by a linker derived from iminodiacetic acid and β-alanine. FDA approved March 27, 2012.
- Indication
Peginesatide is used for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis
- Associated Conditions
- -
- Associated Therapies
- -
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 41
- Registration Number
- NCT01737879
- Locations
- 🇺🇸
Research Site, Chesapeake, Virginia, United States
Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis
- First Posted Date
- 2011-11-24
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 184
- Registration Number
- NCT01478971
- Locations
- 🇺🇸
Research Facility, San Antonio, Texas, United States
Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2012-08-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 59
- Registration Number
- NCT00752791
Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 102
- Registration Number
- NCT00752609
Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA
- Conditions
- Interventions
- First Posted Date
- 2008-05-19
- Last Posted Date
- 2012-06-29
- Lead Sponsor
- Affymax
- Target Recruit Count
- 114
- Registration Number
- NCT00680043
- Locations
- 🇷🇺
Research Facility, Volzhsk, Russian Federation
A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2011-12-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 2
- Registration Number
- NCT00629876
Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2008-01-21
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- Affymax
- Target Recruit Count
- 493
- Registration Number
- NCT00598442
- Locations
- 🇬🇧
Research Facility, London, United Kingdom
Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2008-01-21
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- Affymax
- Target Recruit Count
- 490
- Registration Number
- NCT00598273
- Locations
- 🇵🇷
Research Facility, San Juan, Puerto Rico
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2008-01-18
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- Affymax
- Target Recruit Count
- 823
- Registration Number
- NCT00597584
- Locations
- 🇬🇧
Research Facility, Swansea, United Kingdom
🇩🇪Research Facilities (2), Bremen, Germany
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2008-01-18
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- Affymax
- Target Recruit Count
- 803
- Registration Number
- NCT00597753
- Locations
- 🇺🇸
Research Facilities (2), Norfolk, Virginia, United States
🇺🇸Research Facility, Oshkosh, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.